280 related articles for article (PubMed ID: 19258591)
21. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
22. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
[TBL] [Abstract][Full Text] [Related]
23. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
24. Synergistic effect of two β globin gene cluster mutations leading to the hereditary persistence of fetal hemoglobin (HPFH) phenotype.
Hariharan P; Sawant M; Gorivale M; Manchanda R; Colah R; Ghosh K; Nadkarni A
Mol Biol Rep; 2017 Oct; 44(5):413-417. PubMed ID: 28879539
[TBL] [Abstract][Full Text] [Related]
25. Minihepcidins improve ineffective erythropoiesis and splenomegaly in a new mouse model of adult β-thalassemia major.
Casu C; Chessa R; Liu A; Gupta R; Drakesmith H; Fleming R; Ginzburg YZ; MacDonald B; Rivella S
Haematologica; 2020 Jul; 105(7):1835-1844. PubMed ID: 31582543
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic expression of Hb F in common high Hb F determinants in Thailand: roles of α-thalassemia, 5' δ-globin BCL11A binding region and 3' β-globin enhancer.
Prakobkaew N; Fucharoen S; Fuchareon G; Siriratmanawong N
Eur J Haematol; 2014 Jan; 92(1):73-9. PubMed ID: 24112054
[TBL] [Abstract][Full Text] [Related]
27. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
[TBL] [Abstract][Full Text] [Related]
28. Pathophysiology of beta thalassemia--a guide to molecular therapies.
Thein SL
Hematology Am Soc Hematol Educ Program; 2005; ():31-7. PubMed ID: 16304356
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
30. Alpha and beta thalassemia.
Muncie HL; Campbell J
Am Fam Physician; 2009 Aug; 80(4):339-44. PubMed ID: 19678601
[TBL] [Abstract][Full Text] [Related]
31. [Thalassemia: therapeutic hopes carried by hepcidin].
Vaulont S; Labie D
Med Sci (Paris); 2011 May; 27(5):473-5. PubMed ID: 21609665
[No Abstract] [Full Text] [Related]
32. Fetal hemoglobin silencing in humans.
Oneal PA; Gantt NM; Schwartz JD; Bhanu NV; Lee YT; Moroney JW; Reed CH; Schechter AN; Luban NL; Miller JL
Blood; 2006 Sep; 108(6):2081-6. PubMed ID: 16735596
[TBL] [Abstract][Full Text] [Related]
33. Implication of globin gene expression, hemoglobin F and hemoglobin E levels on β-thalassemia/Hb E disease severity.
Siriworadechkul S; Jindadamrongwech S; Chuncharunee S; Aupparakkitanon S
Ann Clin Lab Sci; 2014; 44(4):437-42. PubMed ID: 25361929
[TBL] [Abstract][Full Text] [Related]
34. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
35. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.
Collins AF; Pearson HA; Giardina P; McDonagh KT; Brusilow SW; Dover GJ
Blood; 1995 Jan; 85(1):43-9. PubMed ID: 7528572
[TBL] [Abstract][Full Text] [Related]
36. Cellular and animal models for the investigation of β-thalassemia.
Nai A; Cordero-Sanchez C; Tanzi E; Pagani A; Silvestri L; Di Modica SM
Blood Cells Mol Dis; 2024 Jan; 104():102761. PubMed ID: 37271682
[TBL] [Abstract][Full Text] [Related]
37. betaMinor-globin messenger RNA accumulation in reticulocytes governs improved erythropoiesis in beta thalassemic mice after erythropoietin complementary DNA electrotransfer in muscles.
Samakoglu S; Fattori E; Lamartina S; Toniatti C; Stockholm D; Heard JM; Bohl D
Blood; 2001 Apr; 97(8):2213-20. PubMed ID: 11290581
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of HPFH and δβ-thalassemia mutations in a Brazilian group with high Hb F levels.
Carrocini GC; Ondei LS; Zamaro PJ; Bonini-Domingos CR
Genet Mol Res; 2011 Dec; 10(4):3213-9. PubMed ID: 22194178
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.
May C; Rivella S; Chadburn A; Sadelain M
Blood; 2002 Mar; 99(6):1902-8. PubMed ID: 11877258
[TBL] [Abstract][Full Text] [Related]
40. Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia.
Gabbianelli M; Morsilli O; Massa A; Pasquini L; Cianciulli P; Testa U; Peschle C
Blood; 2008 Jan; 111(1):421-9. PubMed ID: 17951528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
